Virus-like particles as a vaccine delivery system: Myths and facts

Human Vaccines

Volumn 4, Issue 1, 2008, Pages 5-12

  Roy, Polly ^a   Noad, Rob ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bluetongue; BTV; HPV; Pappilomavirus; Pseudo particles; Rotavirus; SARS; Vaccine; Virus like; VLP

Indexed keywords

GUARDASILTM; MESSENGER RNA; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ADVERSE DRUG REACTION; ANTIBODY TITER; BACULOVIRUS; BLUETONGUE ORBIVIRUS; CALICIVIRUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INFLUENZA VIRUS A; INSECT CELL; NONHUMAN; NOROVIRUS; POLYOMA VIRUS; PORCINE PARVOVIRUS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REOVIRUS; REVIEW; ROTAVIRUS; SARS CORONAVIRUS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

EID: 44649113073     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.1.5559     Document Type: Review

References (100)

1. Miyanohara A, Imamura T, Araki M. et al. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol 1986; 59:176-80.
2. Delchambre M, Gheysen D, Thines D. et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989; 8:2653-60.
3. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59:103-12.
4. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, virus-like particles of blue-tongue virus by the simultaneous expression of four structural proteins. J Virol 1990; 64:5695-700.
5. Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricred T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996; 39:111-9.
6. Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000; 16:273-82.
7. Murata K, Lechmann M, Qiao M, et al. Immunization with heparins C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Narl Acad Sci USA 2003; 100:6753-8.
8. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11:438-44.
9. Maranga L, Rueda P, Antonis AF et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 2002; 59:45-50.
10. Zhou J, Sun XY, Srenzel DJ et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185:251-7.
11. Kirnbauer R, Booy F, Cheng N et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180-4.
12. Sasagawa T, Pushko P, Steers G et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206:126-35.
13. Dupuy C, Buzoni-Gatel D, Touze A et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73:9063-71.
14. Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18:1051-8.
15. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
16. Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183:1485-93.
17. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284-92.
18. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23:2388-94.
19. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
20. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
21. Lopez de Turiso JA, Cortes E, Martinez C et al. Recombinant vaccine for canine parvovirus in dogs. J Virol 1992; 66:2748-53.
22. Martinez C, Dalsgaard K, Lopez de Turiso JA et al. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 1992; 10:684-90.
23. Antonis AF, Bruschke CJ, Rueda P et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006; 24:5481-90.
24. Ball JM, Hardy ME, Atmar RL et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72:1345-53.
25. Guerrero RA, Ball JM, Krater SS et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 2001; 75:9713-22.
26. Ball JM, Graham DY, Opekun AR et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117:40-8.
27. Tacket CO, Sztein MB, Losonsky GA et al. Humoral, mucosal and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7.
28. Li TC, Yamakawa Y, Suzuki K et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71:7207-13.
29. Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001; 19:3476-84.
30. Li TC, Suzaki Y, Ami Y et al. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004; 22:370-7.
31. Goldmann C, Petry H, Frye S et al. Molecular cloning and expression of major structural protein VP1 of the human Polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999; 73:4465-9.
32. Caparros-Wanderley W, Clark B, Griffin BE. Effect of dose and long-term storage on the immunogenicity of murine Polyomavirus VP1 virus-like particles. Vaccine 2004; 22:352-61.
33. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VPO, VP3 and VP1 proteins by comparison to particles derived from rhe expressed poliovirus polyprotein. Virology 1993; 192:512-24.
34. Kibenge FS, Qjan B, Nagy E et al. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can J Vet Res 1999; 63:49-55.
35. French TJ, Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 1990; 64:1530-6.
36. Belyaev AS, Hails RS, Roy E High-level expression of five foreign genes by a single recombinant baculovirus. Gene 1995; 156:229-33.
37. Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: coexpression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Research 1993; 21:1219-23.
38. Roy P. Orbiviruses In: Fields' Virology (D. M. Knipe & P. M. Howley., eds.), Fourth Edition. Lippincott Williams & Wilkins 2001; Chapter 56:1835-69.
39. Roy P, French T, Erasmus BJ. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 1992; 10:28-32.
40. Roy P, Bishop DH, LeBlois H et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994; 12:805-11.
41. Roy P, Urakawa T, Van Dijk AA et al. Recombinant virus vaccine for bluetongue disease in sheep. J Virol 1990; 64:1998-2003.
42. Sahara M, Parker M, Aha P et al. Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins. J Virol 1991; 65:6994-7.
43. Jiang B, Estes MK, Barone C et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999; 17:1005-13.
44. Madore HP, Estes MK, Zarley CD et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 1999; 17:2461-71.
45. Kim Y, Nielsen PR, Hodgins D et al. Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. Vaccine 2002; 20:1248-58.
46. Nguyen TV, Yuan L, MS PA et al. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine 2006; 24:2302-16.
47. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE et al. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003; 21:3885-900.
48. Parez N, Fourgeux C, Mohamed A et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 2006; 80:1752-61.
49. Agnello D, Herve CA, Lavaux A et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 2006; 80:3823-32.
50. Yamshchikov GV, Ritter GD, Vey M et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 1995; 214:50-8.
51. Baumert TF, Ito S, Wong DT et al. Hepatitis C virus structural proteins assemble into virus-like particles in insect cells. J Virol 1998; 72:3827-36.
52. Latham T, Galarza JM. Formation or wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001: 75:6154-65.
53. Jeong SH, Qiao M, Nascimbeni M et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78:6995-7003.
54. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004; 576:174-8.
55. Ho Y, Lin PH, Liu CY et al. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004; 318:833-8.
56. Yao Q, Kuhlmann FM, Eller R er al. Production and characterization of simian - human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 2000; 16:227-36.
57. Wagner R, Deml L, Notka F et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 1996; 39:93-103.
58. Yao Q, Vuong V, Li M et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 2002; 20:2537-45.
59. Lechmann M, Murata K, Satoi J et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34:417-23.
60. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18:244-51.
61. Pushko P, Tumpey TM, Bu F et al. Influenza virus-like particles comprised of the HA, NA and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23:5751-9.
62. Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004; 15:513-7.
63. Beyer T, Herrmann M, Reiser C et al. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr Drug Targets Infect Disord 2001; 1:287-302.
64. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003; 63:3478-82.
65. Sedlik C, Saron M, Sarraseca J et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc Natl Acad Sci USA 1997; 94:7503-8.
66. Fausch SC, Da Silva, DM, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine 2005; 23:1720-9.
67. Lo-Man R, Rueda P, Sedlik C et al. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28:1401-7.
68. Charpilienne A, Nejmeddine M BM, Parez N, Neumann E, Hewat E, Trugnan G, Cohen J. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells, J Biol Chem 2001; 276:29361-7.
69. Ghosh MK, Deriaud E, Saron MF et al. Induction of proteccive antiviral cytotoxic T-cells by a tubular structure capable of carrying large foreign sequences. Vaccine 2002; 20:1369-77.
70. Ghosh MK, Borca MV, Roy P. Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4 + Th cell and protective humoral responses. Virology 2002; 302:383-92.
71. Larke N, Murphy A, Wirblich C et al. Induction of human immunodeficiency virus type 1-specific T-cells by a bluetongue virus tubule-vectored vaccine prime-recombinani modified virus Ankara boost regimen. J Virol 2005; 79:14822-33.
72. Lindenburg CE, Stolte I, Langendam MW et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002; 20:2343-7.
73. Kirnbauer R, Taub J, Greenstone H et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67:6929-36.
74. Jiang X, Wang M, Graham DY et al. Expression, self-assembly and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:6527-32.
75. Laurent S, Vautherot JF, Madelaine MF et al. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol 1994; 68:6794-8.
76. Pletneva MA, Sosnovtsev SV, Sosnovtseva SA et al. Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells. Virus Res 1998: 55:129-41.
77. Hale AD, Crawford SE, Ciarlet M et al. Expression and self-assembly of Grimsby virus: antigenic distinction from Norwalk and Mexico viruses. Clin Diagn Lab Immunol 1999; 6:142-5.
78. Bellior G, Noel JS, Li JF et al. Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of "Norwalk-like viruses." J Clin Microbiol 2001; 39:4288-95.
79. Brown CS, Van Lent JW, Vlak JM et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol 1991; 65:2702-6.
80. Chrisrensen J, Alexandersen S, Bloch B et al. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J Gen Virol 1994; 75:149-55.
81. Hoque M, Shimizu N, Ishizu K et al. Chimeric virus-like particle formation of adeno-associated virus. Biochem Biophys Res Commun 1999; 266:371-6.
82. Koch G, van Roozelaar DJ, Verschueren CA et al. Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus. Vaccine 1995; 13:763-70.
83. Noteborn MH, Verschueren CA, Koch G et al. Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J Gen Virol 1998; 79:3073-7.
84. Albina E, Truong C, Hutet E et al. An experimental model for post-weaning multisystemic wasting syndrome (PMWS) in growing piglets. J Comp Pathol 2001; 125:292-303.
85. Kim Y, Kim J, Kang K et al. Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system. J Vet Sci 2002; 3:19-23.
86. Kosukegawa A, Arisaka F, Takayama M et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim Biophys Acta 1996; 1290:37-45-
87. Chang D, Fung CY, Ou WC et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 1997; 78:1435-9.
88. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993; 192:512-24.
89. Crawford SE, Labbe M, Cohen J et al. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 1994; 68:5945-22.
90. Overton HA, Fujii Y, Price IR et al. The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology 1989; 170:107-16.
91. Rasmussen L, Battles JK, Ennis WH et al. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 1990; 178:435-51.
92. Morikawa S, Booth TF, Bishop DH. Analyses of the requirements lot the synthesis of virus-like panicles by feline immunodeficiency virus gag using baculovirus vectors. Virology 1991; 183:288-97.
93. Thomsen DR, Meyer AL, Post LE. Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. J Gen Virol 1992; 73:1819-24.
94. Rafnar B, Tobin GJ, Nagashima K et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res 1998; 53:107-20.
95. Kakker N, Mikhailov M, Nermut MV et al. Bovine leukemia virus Gag particle assembly in insect cells: Formation of chimeric particles by domain-switched leukemia/lentitivirus Gag polyprotein. Virology 1999; 2:303-18.
96. Johnson MC, Scobie HM, Vogt VM. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J Virol 2001; 75:4407-12.
97. Nagy E, Huber P, Krell PJ et al. Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. J Gen Virol 1991; 72:753-6.
98. Berenbaugh M, Yu M, Kuehl K et al. Nucleocapsid-and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res 1995; 38:111-24.
99. Fernandez-Arias A, Risco C, Martinez S et al. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J Gen Virol 1998; 79:1047-54.
100. Martinez-Torrecuadrada JL, Saubi N, Pages-Mante A et al. Structure dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. Vaccine 2003; 21:3342-50.